Concept

fitness

D1 Training introduces its athletic-based fitness concept to the Fox Valley Area

D1 Training, a leading fitness concept utilizing the five core tenets of athletic-based training, has opened a location serving the Fox Valley area. The group fitness facility employs a sports-science backed training regimen led by certified trainers to help people of all ages achieve their sport and fitness goals. The training center located in Aurora at 403 S. Route 59 hosted its grand opening Sept. 12.

The first D1 Training center in the Chicago area is owned and operated by longtime friends and business partners, Jeffrey Cantieri and Paul Bullard, both of whom wanted to make an impact in their community and help change lives by inspiring and motivating people to reach their fitness and sports goals.

        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

 

“It’s always been a dream of mine to own a business like D1, because it can have such a positive impact in people’s lives,” said Bullard. “Our facility caters to everyone, whether you’re looking to get or stay fit or you’re working toward sports-specific goals. We have trainers, known as coaches at D1, that can help people of any age and fitness level — making sure everyone feels welcome is our top priority.”

With safety at a premium, D1 Fox Valley has equipment and procedures in place to ensure all members and employees are protected. D1 Fox Valley has installed brand new HVAC equipment with an ionization system that helps kill germs and they will conduct temperature checks for everyone entering the facility. Equipment will be cleaned every hour and class size will be limited with members being spaced 6 feet apart.

D1 Training Fox Valley offers five age-based fitness programs including Rookie (ages 7-11), Developmental (ages 12-14), Prep (ages 15-18), Boot Camp (adults) and Strength Training (adults). They also offer personal, small group and team training. Each fitness program is based on D1’s 5-Star Training philosophy incorporating: dynamic warm-up, performance, strength, core and conditioning, and cool down.

Plus, every workout is expertly-designed by D1’s National Training Panel, led by a certified trainer, and built around the concept of periodization which builds week-upon-week to create a well-rounded program targeted to reach specific goals. Some additional benefits of D1’s 5-Star Training include utilization of the latest science in training and physiology, 1on1 goal setting and tracking of results, adaptable and personalized workouts, and more.

“Jeffrey and Paul are a passionate and knowledgeable pair making them perfect to bring the D1 Training experience to the Chicagoland area,” said the brand’s Chief Operating Officer, Dan Murphy. “We’re thrilled to welcome them to the D1 family and are confident in their ability to show the Chicago area what they’ve been missing out on. D1 is a one-of-a-kind fitness experience that’s built to help people efficiently reach their fitness goals. Our strong network of franchisees embodies our core values to bring the D1 Training vision to life, and we know Jeffrey and Paul will do just that in Aurora and its surrounding communities.”

For more information on D1 Training Fox Valley in Aurora, visit www.d1trainingfoxvalley.com or call (630)

Read More
medicine

Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis

NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced that Dr. Richard Granstein, M.D., Chairman of Dermatology at Weill Cornell Medicine in New York City, will initiate an investigator-led clinical trial with a Biohaven CGRP-receptor antagonist for the treatment of plaque psoriasis.

Vlad Coric M.D., Chief Executive Officer of Biohaven commented, “Biohaven’s neuroinnovation portfolio is powered by a combination of strong science and patient need. Dr. Granstein is a foremost expert in the CGRP-related biology of dermatological conditions, which has been a focus of his research for nearly two decades. We are committed to following the science of CGRP-receptor antagonism across disease states and Dr. Granstein’s pioneering work affirms that neuropeptide CGRP may play a critical role in plaque psoriasis.  This scientific foundation, together with a recognized need for more safe and effective treatment options for people suffering with psoriasis, has inspired our meaningful collaboration.”

The investigator-led clinical trial will explore whether treatment with one of Biohaven’s CGRP-receptor antagonists will reduce the severity of disease and percentage of area affected as measured by patients’ Psoriasis Activity Severity Index (PASI) score after 16 weeks of treatment as compared to placebo. In addition, the study will assess the potential impact on itch and patient quality-of-life measures.

Dr. Granstein commented, “The animal models and clinical reports of CGRP in psoriasis suggest that CGRP receptor antagonism could alleviate the severity of disease. This clinical study will enable us to evaluate this therapeutic candidate’s efficacy, the findings of which will be the first step in bringing this novel, translational idea to patients. Pathways by which the nervous system exerts regulatory effects on immunity may prove to provide important druggable targets for a range of inflammatory disorders.”

Biohaven’s CGRP-receptor antagonist platform includes Nurtec™ ODT (rimegepant) and zavegepant. Nurtec ODT™ was approved by the FDA in February 2020 for the acute treatment of migraine. Biohaven filed a supplemental New Drug Application (sNDA) for Nurtec™ ODT (rimegepant) for the preventive treatment of migraine earlier this year which was accepted for review in October 2020. The Prescription Drug User Fee Act (PDUFA) goal date for completion of the FDA review of the preventive sNDA is set for 2Q2021.

Zavegepant is a third generation, high affinity, selective and unique, small molecule CGRP receptor antagonist that is structurally distinct from rimegepant. Zavegepant may be suitable for multiple routes of delivery including nasal, subcutaneous, inhalation or oral administration. Positive results were announced in late 2019 from a Phase 2/3 study of intranasal zavegepant in the acute treatment of migraine, and the company plans to initiate an additional Phase 3 study before the end of 2020. Biohaven also initiated a Phase 2 trial with intranasal zavegepant in April 2020 in collaboration with Thomas Jefferson University in Philadelphia, PA, to study the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response in pulmonary function which in

Read More